Abstract: Foreword, John G. Bartlett, The Johns Hopkins University School of Medicine, Baltimore, Maryland HIV-1 Protease as a Target for AIDS Therapy, John W. Erickson Discovery and Early Development of Saquinavir, Ian B. Duncan and Sally Redshaw Discovery and Early Development of Ritonavir and ABT-378, Dale J. Kemp Discovery and Early Development of Indinavir, Bruce D. Dorsey and Joseph P. Vacca Discovery and Development of Nelfinavir (Viracept), Siegfriend H. Reich Design and Synthesis of Amprenavir, A Novel HIV Protease Inhibitor, R. D. Tung, D. J. Livingston, B. G. Rao, E. E. Kim, C. T. Baker, J. S. Boger, S. P. Chambers, D. D. Delhinger, M. Dwyer, L. Elsayed, J. Fulghum, B. Li, M. A. Murcko, M. A. Navia, P. Novak, S. Pazhanisamy, C. Stuver, and J.A. Thomson HIV Protease Inhibitors in Early Development, R. Alan Chrusciel, Judith A. Nicholas, and Suvit Thaisrivongs Pharmacology and Drug Interactions of HIV Protease Inhibitors, Charles W. Flexner Beneficial Pharmokinetic Interactions: Are Two Protease Inhibitors Better than One?, Charles W. Flexner Protease Inhibitors: Clinical Efficacy, Roy M. Gulick Toxicities and Adverse Effects of Protease Inhibitors, Marshall J. Glesby Resistance to HIV-1 Protease Inhibitors, Benjamin Young and Daniel R. Kuritzkes Expedited Drug Approval and HIV Protease Inhibitors, Jeff Murray Use of Protease Inhibitors in the Management of HIV/AIDS, Richard C. Ogden and Charles W. Flexner
Publication Year: 2001
Publication Date: 2001-01-24
Language: en
Type: book
Access and Citation
Cited By Count: 112
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot